Vinpocetine - instructions for use, dose, side effects, contraindications

Improves the metabolism of the brain, increasing the intake of glucose and oxygen by brain tissue. Increases the resistance of brain cells to hypoxia, facilitating the transport of oxygen and substrates of energy supply to tissues (due to reduced affinity for erythrocytes, increased absorption and metabolism of glucose,switching it to an energetically more advantageous aerobic direction). It promotes the accumulation in the tissues of cyclic adenosine monophosphate (cAMP) and adenosine triphosphate (ATP) (inhibitionCa²⁺-dependent phosphodiesterase (PDE) and stimulation of adenylate cyclase), an increase in the content of catecholamines in the brain tissues. Stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. The vasodilating effect is associated with a direct relaxing effect on the smooth muscles of the vessels of the predominantly brain. Vinpocetine does not cause the phenomenon of "stealing", primarily enhances the blood supply of the ischemic region of the brain, while not changing the blood supply of intact areas.

Improves microcirculation in the brain due to a decrease in platelet aggregation, decrease in blood viscosity, increase in the deformability of erythrocytes. Increases cerebral blood flow; reduces the resistance of cerebral vessels without significantly affecting the systemic blood circulation (blood pressure (BP), minute blood volume (IOC), heart rate reduction (HR)).The therapeutic effect develops approximately 1 week after the start of the drug.

Pharmacokinetics:

When ingested quickly and completely absorbed in the gastrointestinal tract (GIT) (mainly in the proximal GI tract). Bioavailability when taken on an empty stomach is about 70%. T_Сmах in blood plasma - 1 hour, in tissues - 2-4 hours. When passing through the wall of the intestine is not exposed to metabolism. When introducing repeated doses, the kinetics is linear.

The connection with proteins - 66%, clearance - 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. Penetrates into breast milk (0.25% within the first hour), through the placental barrier. T_1/2 - 3.54-6.12 h. It is excreted by the kidneys and intestines in the ratio 3: 2.

Indications:

Neurology: as a symptomatic agent for various forms of cerebral circulatory insufficiency (ischemic stroke, restorative stage of hemorrhagic stroke, consequences of a stroke, transient ischemic attack, vascular dementia, vertebrobasilar insufficiency, cerebrovascular atherosclerosis, posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or retinal vein).

Perceptive hearing loss, Meniere's disease, idiopathic tinnitus.

Contraindications:

Hypersensitivity, acute phase of hemorrhagic stroke, severe ischemic heart disease (CHD), severe heart rhythm disturbances, pregnancy, lactation, age under 18 years.

Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.

Carefully:With caution apply the drug in patients with IHD (severe course).

Dosing and Administration:

Inside, after eating.

The initial dose is 15 mg / day, the standard daily dose is 5-10 mg 3 times a day. The maximum daily dose is 30 mg. The course of treatment - at least 1 - 3 months.

Side effects:

From the CAS side: changes on the ECG (depression of the ST segment, prolongation of the Q-T interval); tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (often decrease).

From the side of the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dry mouth, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia.

Overdose:

Symptoms: increased manifestation of the above side effects (except allergic reactions).

Treatment: gastric lavage, reception of activated charcoal, symptomatic treatment.

Interaction:

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Despite the lack of data confirming the possibility of interaction, it is advisable to use caution when concurrent with the use of central medication, antiarrhythmic drugs and anticoagulants.

Special instructions:In the case of the initial extension of the Q-T interval, as well as with simultaneous application with drugs extending the Q-T interval, periodic ECG monitoring is necessary during the treatment with vinpocetine.

Form release / dosage:Tablets 5 mg.

Packaging:

10 tablets per contour cell packaging made of polyvinylchloride film and aluminum foil. 3, 5 or 6 contour mesh packages together with instructions for use in a cardboard pack.

Storage conditions:

In a dry, the dark place at a temperature of no higher than 25 ° C.

In a place inaccessible to children.

Shelf life:

2 years.

Do not use after the time specified on the package.

Terms of leave from pharmacies:On prescription

Registration number:LSR-009342/09

Date of registration:19.11.2009

Expiration Date:Unlimited

The owner of the registration certificate:LEKFARM, SOOO LEKFARM, SOOO Republic of Belarus

Manufacturer: & nbsp

LEKFARM, SOOO Republic of Belarus

Information update date: & nbsp18.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)